1 Disclaimer All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate and ...

OmniAb, Inc. (NASDAQ:OABI) Research & Technology Virtual Event and 3Q23 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Matthew Foehr - President and CEO Todd Pettingill - VP, Business Development and Strategy Bill Harriman - SVP, Antibody Discovery Bob Chen - Senior Director, Discovery Systems Doug Krafte - SVP, Ion Channels Kurt Gustafson - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Puneet Souda - Leerink Partners Stephen Willey - Stifel Nishant Gand ...

For the Transition Period From ______ to ______. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-40720 Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursu ...

OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OMNIAB, INC. (Exact na ...

Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report. (1) Represents the unique number of partners that have an active program or have executed a license agreement in advance of initiating an active program. (2) Represent ...

OmniAb, Inc. (NASDAQ:OABI) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President, CEO Conference Call Participants Nishant Gandhi - Truist Securities Stephen Willey - Stifel Joe Pantginis - H.C. Wainwright Puneet Souda - SVB Securities Steven Mah - TD Securities Matt Hewitt - Craig-Hallum Capital Group Operator Good morning, and welcome to the OmniAb Inc.'s First Quarter 2023 Financial Results and Business Update Conference Call. At this ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

1 Disclaimer Information regarding partnered products and programs comes from information publicly released by our partners. | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------|--------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Introduction | | | | | | | | | | Matt Foehr | | | | | | | | | | OUR BUSINESS MODEL IS FOCUSED ON LICENSING OUR PROPRIETARY DISCOVERY TECHNO ...

OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President and CEO Conference Call Participants Nishant Gandhi - Truist Securities Joseph Pantginis - H.C. Wainwright & Co. Steven Mah - TD Cowen Puneet Souda - SVB Securities Yuan Zhi - B. Riley FBR Operator Good afternoon, ladies and gentlemen, and welcome to the OmniAb, Inc., Fourth Quarter and Full Year of '22 Earnings Conference Call. At this time all lines are in ...